CDNF and CDNF variants- novel therapy for ALS

Description of the granted funding

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, where motoneurons selectively die, leading to muscle atrophy and paralysis. There is currently no therapy for ALS. Patients die on average 3-5 years from time of diagnosis. Endoplasmic reticulum (ER) stress plays an important role in the pathophysiology of ALS. CDNF is a novel ER stress regulating protein and a promising drug candidate for ALS. A single injection of CDNF increases survival, improves motor coordination, protects MNs in spinal cord and reduces ER stress in SOD1 mouse model of ALS. In this project I will 1) identify the effect of chronic intraventricular infusion of CDNF in TDP43 rats and mice 2) Test and compare the therapeutic effect of CDNF variant and CDNF in vitro in MN cultures and in genetic models of ALS in vivo; and 3) Study how CDNF regulates ER stress in MNs from animal models of ALS and MNs generated from ALS patient-derived iPS cells, and effects on SOD1 and TDP-43 protein aggregation
Show more

Starting year

2017

End year

2022

Granted funding

Merja Voutilainen Orcid -palvelun logo
434 485 €

Related funding decisions

335803
Research costs of Academy Research Fellows(2020)
200 000 €
314233
Research costs of Academy Research Fellows(2017)
330 000 €

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Other information

Funding decision number

309708

Fields of science

Neurosciences

Research fields

Neurotiede

Identified topics

brain, neuroscience